{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T23:09:47Z","timestamp":1793574587187,"version":"4.5.0"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Rev and Rep"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Despite advances in surgical resection, radiation, and chemotherapy, glioblastoma remains a lethal condition driven by intrinsic heterogeneity, therapy resistance, and an immunosuppressive tumour microenvironment. Mesenchymal stromal cells (MSCs) and their secretomes, comprising cytokines, growth factors, and extracellular vesicles, have emerged as promising therapeutic candidates due to their tumour-homing properties and anti-inflammatory and immunomodulatory potential. However, recent evidence reveals a paradox: MSC secretomes exhibit both anti-inflammatory\/immunomodulatory potential and pro-tumorigenic activities, depending on MSC source, passage number, and environmental and manufacturing contexts. In this review, we critically examine the molecular mechanisms underlying these opposing effects, synthesising evidence on how MSC source, donor variability, passage number, and environmental priming\/licensing (e.g., hypoxia, inflammatory licensing) dictate secretome composition and function. We identify critical manufacturing determinants, including the necessity for upper passage limits and standardised isolation protocols, and propose a translational framework that integrates mechanism-based potency assays, such as nuclear factor-\u03baB (NF-\u03baB) reporter systems and multi-donor mixed lymphocyte reactions, to predict clinical activity. Establishing these robust quality controls and mechanistic release and rejection criteria will be essential to resolve the functional plasticity of secretomes and enable the safe translation of MSC-based therapies for glioblastoma.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical Abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1007\/s12015-026-11082-z","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T02:32:02Z","timestamp":1771036322000},"page":"1537-1549","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pro- and Anti-tumorigenic Effects of MSC Secretome in Glioblastoma: Mechanisms and Therapeutic Implications"],"prefix":"10.1007","volume":"22","author":[{"given":"Atiyeh","family":"Asadpour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme S.","family":"Cottrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darius","family":"Widera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,14]]},"reference":[{"issue":"8","key":"11082_CR1","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis, D. N., Perry, A., Wesseling, P., Brat, D. J., Cree, I. A., Figarella-Branger, D., et al. (2021). The 2021 WHO classification of tumors of the central nervous system: A summary. Neuro Oncol, 23(8), 1231\u20131251. https:\/\/doi.org\/10.1093\/neuonc\/noab106","journal-title":"Neuro Oncol"},{"issue":"5","key":"11082_CR2","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","volume":"10","author":"R Stupp","year":"2009","unstructured":"Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, R. C., et al. (2009). Effects of radiotherapy with concomitant and adjuvant Temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. The Lancet Oncology, 10(5), 459\u2013466. https:\/\/doi.org\/10.1016\/S1470-2045(09)70025-7","journal-title":"The Lancet Oncology"},{"issue":"10","key":"11082_CR3","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J., et al. (2005). Radiotherapy plus concomitant and adjuvant Temozolomide for glioblastoma. New England Journal of Medicine, 352(10), 987\u2013996. https:\/\/doi.org\/10.1056\/NEJMoa043330","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"11082_CR4","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","volume":"17","author":"RG Verhaak","year":"2010","unstructured":"Verhaak, R. G., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., et al. (2010). Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell, 17(1), 98\u2013110. https:\/\/doi.org\/10.1016\/j.ccr.2009.12.020","journal-title":"Cancer Cell"},{"issue":"6190","key":"11082_CR5","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1126\/science.1254257","volume":"344","author":"AP Patel","year":"2014","unstructured":"Patel, A. P., Tirosh, I., Trombetta, J. J., Shalek, A. K., Gillespie, S. M., Wakimoto, H., et al. (2014). Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science, 344(6190), 1396\u20131401. https:\/\/doi.org\/10.1126\/science.1254257","journal-title":"Science"},{"issue":"3","key":"11082_CR6","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.gendis.2016.04.007","volume":"3","author":"SY Lee","year":"2016","unstructured":"Lee, S. Y. (2016). Temozolomide resistance in glioblastoma multiforme. Genes Dis, 3(3), 198\u2013210. https:\/\/doi.org\/10.1016\/j.gendis.2016.04.007","journal-title":"Genes Dis"},{"issue":"3","key":"11082_CR7","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.ccell.2017.02.009","volume":"31","author":"DF Quail","year":"2017","unstructured":"Quail, D. F., & Joyce, J. A. (2017). The microenvironmental landscape of brain tumors. Cancer Cell, 31(3), 326\u2013341. https:\/\/doi.org\/10.1016\/j.ccell.2017.02.009","journal-title":"Cancer Cell"},{"issue":"17","key":"11082_CR8","doi-asserted-by":"publisher","first-page":"4175","DOI":"10.1158\/1078-0432.CCR-17-1846","volume":"24","author":"K Woroniecka","year":"2018","unstructured":"Woroniecka, K., Chongsathidkiet, P., Rhodin, K., Kemeny, H., Dechant, C., Farber, S. H., et al. (2018). T-Cell exhaustion signatures vary with tumor type and are severe in glioblastoma. Clinical Cancer Research, 24(17), 4175\u20134186. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-1846","journal-title":"Clinical Cancer Research"},{"issue":"7120","key":"11082_CR9","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/nature05236","volume":"444","author":"S Bao","year":"2006","unstructured":"Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., et al. (2006). Glioma stem cells promote radioresistance by Preferential activation of the DNA damage response. Nature, 444(7120), 756\u2013760. https:\/\/doi.org\/10.1038\/nature05236","journal-title":"Nature"},{"issue":"8","key":"11082_CR10","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/nrn2175","volume":"8","author":"RK Jain","year":"2007","unstructured":"Jain, R. K., di Tomaso, E., Duda, D. G., Loeffler, J. S., Sorensen, A. G., & Batchelor, T. T. (2007). Angiogenesis in brain tumours. Nature Reviews Neuroscience, 8(8), 610\u2013622. https:\/\/doi.org\/10.1038\/nrn2175","journal-title":"Nature Reviews Neuroscience"},{"issue":"1","key":"11082_CR11","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nn.4185","volume":"19","author":"D Hambardzumyan","year":"2016","unstructured":"Hambardzumyan, D., Gutmann, D. H., & Kettenmann, H. (2016). The role of microglia and macrophages in glioma maintenance and progression. Nature Neuroscience, 19(1), 20\u201327. https:\/\/doi.org\/10.1038\/nn.4185","journal-title":"Nature Neuroscience"},{"key":"11082_CR12","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.semcancer.2019.07.028","volume":"60","author":"BS Hill","year":"2020","unstructured":"Hill, B. S., Sarnella, A., D\u2019Avino, G., & Zannetti, A. (2020). Recruitment of stromal cells into tumour microenvironment promote the metastatic spread of breast cancer. Semin Cancer Biol, 60, 202\u2013213. https:\/\/doi.org\/10.1016\/j.semcancer.2019.07.028","journal-title":"Semin Cancer Biol"},{"issue":"5","key":"11082_CR13","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1002\/jor.1100090504","volume":"9","author":"AI Caplan","year":"1991","unstructured":"Caplan, A. I. (1991). Mesenchymal stem cells. Journal of Orthopaedic Research, 9(5), 641\u2013650. https:\/\/doi.org\/10.1002\/jor.1100090504","journal-title":"Journal of Orthopaedic Research"},{"key":"11082_CR14","doi-asserted-by":"publisher","first-page":"461718","DOI":"10.1155\/2012\/461718","volume":"2012","author":"H Orbay","year":"2012","unstructured":"Orbay, H., Tobita, M., & Mizuno, H. (2012). Mesenchymal stem cells isolated from adipose and other tissues: Basic biological properties and clinical applications. Stem Cells Int, 2012, 461718. https:\/\/doi.org\/10.1155\/2012\/461718","journal-title":"Stem Cells Int"},{"key":"11082_CR15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1476-9255-2-8","volume":"2","author":"JM Ryan","year":"2005","unstructured":"Ryan, J. M., Barry, F. P., Murphy, J. M., & Mahon, B. P. (2005). Mesenchymal stem cells avoid allogeneic rejection. Journal of Inflammation (London), 2, 8. https:\/\/doi.org\/10.1186\/1476-9255-2-8","journal-title":"Journal of Inflammation (London)"},{"issue":"1","key":"11082_CR16","doi-asserted-by":"publisher","first-page":"62","DOI":"10.5581\/1516-8484.20130017","volume":"35","author":"V Machado Cde","year":"2013","unstructured":"Machado Cde, V., Telles, P. D., & Nascimento, I. L. (2013). Immunological characteristics of mesenchymal stem cells. Rev Bras Hematol Hemoter, 35(1), 62\u201367. https:\/\/doi.org\/10.5581\/1516-8484.20130017","journal-title":"Rev Bras Hematol Hemoter"},{"issue":"4","key":"11082_CR17","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/scrt488","volume":"5","author":"P Lohan","year":"2014","unstructured":"Lohan, P., Coleman, C. M., Murphy, J. M., Griffin, M. D., Ritter, T., & Ryan, A. E. (2014). Changes in immunological profile of allogeneic mesenchymal stem cells after differentiation: Should we be concerned? Stem Cell Research & Therapy, 5(4), 99. https:\/\/doi.org\/10.1186\/scrt488","journal-title":"Stem Cell Research & Therapy"},{"issue":"1","key":"11082_CR18","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3727\/096368910X","volume":"20","author":"DC Ding","year":"2011","unstructured":"Ding, D. C., Shyu, W. C., & Lin, S. Z. (2011). Mesenchymal stem cells. Cell Transplantation, 20(1), 5\u201314. https:\/\/doi.org\/10.3727\/096368910X","journal-title":"Cell Transplantation"},{"key":"11082_CR19","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1478-811X-9-12","volume":"9","author":"R Hass","year":"2011","unstructured":"Hass, R., Kasper, C., Bohm, S., & Jacobs, R. (2011). Different populations and sources of human mesenchymal stem cells (MSC): A comparison of adult and neonatal tissue-derived MSC. Cell Commun Signal, 9, 12. https:\/\/doi.org\/10.1186\/1478-811X-9-12","journal-title":"Cell Commun Signal"},{"issue":"7","key":"11082_CR20","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/j.yexcr.2007.12.022","volume":"314","author":"D Noel","year":"2008","unstructured":"Noel, D., Caton, D., Roche, S., Bony, C., Lehmann, S., Casteilla, L., et al. (2008). Cell specific differences between human adipose-derived and mesenchymal-stromal cells despite similar differentiation potentials. Experimental Cell Research, 314(7), 1575\u20131584. https:\/\/doi.org\/10.1016\/j.yexcr.2007.12.022","journal-title":"Experimental Cell Research"},{"issue":"5","key":"11082_CR21","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1007\/s12015-022-10369-1","volume":"18","author":"D Jovic","year":"2022","unstructured":"Jovic, D., Yu, Y., Wang, D., Wang, K., Li, H., Xu, F., et al. (2022). A brief overview of global trends in MSC-Based cell therapy. Stem Cell Rev Rep, 18(5), 1525\u20131545. https:\/\/doi.org\/10.1007\/s12015-022-10369-1","journal-title":"Stem Cell Rev Rep"},{"issue":"4","key":"11082_CR22","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/14653240600855905","volume":"8","author":"M Dominici","year":"2006","unstructured":"Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F., Krause, D., et al. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy, 8(4), 315\u2013317. https:\/\/doi.org\/10.1080\/14653240600855905","journal-title":"Cytotherapy"},{"issue":"1","key":"11082_CR23","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s12015-021-10231-w","volume":"18","author":"U Galderisi","year":"2022","unstructured":"Galderisi, U., Peluso, G., & Di Bernardo, G. (2022). Clinical trials based on mesenchymal stromal cells are exponentially increasing: Where are we in recent years? Stem Cell Rev Rep, 18(1), 23\u201336. https:\/\/doi.org\/10.1007\/s12015-021-10231-w","journal-title":"Stem Cell Rev Rep"},{"issue":"6","key":"11082_CR24","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1002\/sctm.17-0051","volume":"6","author":"AI Caplan","year":"2017","unstructured":"Caplan, A. I. (2017). Mesenchymal stem cells: Time to change the Name! Stem Cells Transl Med, 6(6), 1445\u20131451. https:\/\/doi.org\/10.1002\/sctm.17-0051","journal-title":"Stem Cells Transl Med"},{"key":"11082_CR25","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jare.2024.05.004","volume":"70","author":"CM Trigo","year":"2025","unstructured":"Trigo, C. M., Rodrigues, J. S., Camoes, S. P., Sola, S., & Miranda, J. P. (2025). Mesenchymal stem cell secretome for regenerative medicine: Where do we stand? Journal of Advanced Research, 70, 103\u2013124. https:\/\/doi.org\/10.1016\/j.jare.2024.05.004","journal-title":"Journal of Advanced Research"},{"key":"11082_CR26","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.biochi.2018.07.008","volume":"155","author":"ED Gomes","year":"2018","unstructured":"Gomes, E. D., Vieira de Castro, J., Costa, B. M., & Salgado, A. J. (2018). The impact of mesenchymal stem cells and their secretome as a treatment for gliomas. Biochimie, 155, 59\u201366. https:\/\/doi.org\/10.1016\/j.biochi.2018.07.008","journal-title":"Biochimie"},{"issue":"1","key":"11082_CR27","doi-asserted-by":"publisher","first-page":"188582","DOI":"10.1016\/j.bbcan.2021.188582","volume":"1876","author":"B Nowak","year":"2021","unstructured":"Nowak, B., Rogujski, P., Janowski, M., Lukomska, B., & Andrzejewska, A. (2021). Mesenchymal stem cells in glioblastoma therapy and progression: How one cell does it all. Biochimica Et Biophysica Acta - Reviews on Cancer, 1876(1), 188582. https:\/\/doi.org\/10.1016\/j.bbcan.2021.188582","journal-title":"Biochimica Et Biophysica Acta - Reviews on Cancer"},{"issue":"21","key":"11082_CR28","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1093\/jnci\/djh299","volume":"96","author":"M Studeny","year":"2004","unstructured":"Studeny, M., Marini, F. C., Dembinski, J. L., Zompetta, C., Cabreira-Hansen, M., Bekele, B. N., et al. (2004). Mesenchymal stem cells: Potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. Journal of the National Cancer Institute, 96(21), 1593\u20131603. https:\/\/doi.org\/10.1093\/jnci\/djh299","journal-title":"Journal of the National Cancer Institute"},{"issue":"1","key":"11082_CR29","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41420-022-01107-0","volume":"8","author":"X Li","year":"2022","unstructured":"Li, X., Fan, Q., Peng, X., Yang, S., Wei, S., Liu, J., et al. (2022). Mesenchymal\/stromal stem cells: Necessary factors in tumour progression. Cell Death Discov, 8(1), 333. https:\/\/doi.org\/10.1038\/s41420-022-01107-0","journal-title":"Cell Death Discov"},{"key":"11082_CR30","doi-asserted-by":"publisher","first-page":"115790","DOI":"10.1016\/j.biopha.2023.115790","volume":"173","author":"J Park","year":"2024","unstructured":"Park, J., Park, S. A., Kim, Y. S., Kim, D., Shin, S., Lee, S. H., et al. (2024). Intratumoral IL-12 delivery via mesenchymal stem cells combined with PD-1 Blockade leads to long-term antitumor immunity in a mouse glioblastoma model. Biomedicine & Pharmacotherapy, 173, 115790. https:\/\/doi.org\/10.1016\/j.biopha.2023.115790","journal-title":"Biomedicine & Pharmacotherapy"},{"issue":"4","key":"11082_CR31","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.jcyt.2017.02.002","volume":"19","author":"BC Parker Kerrigan","year":"2017","unstructured":"Parker Kerrigan, B. C., Shimizu, Y., Andreeff, M., & Lang, F. F. (2017). Mesenchymal stromal cells for the delivery of oncolytic viruses in gliomas. Cytotherapy, 19(4), 445\u2013457. https:\/\/doi.org\/10.1016\/j.jcyt.2017.02.002","journal-title":"Cytotherapy"},{"key":"11082_CR32","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.3389\/fimmu.2018.02837","volume":"9","author":"JR Ferreira","year":"2018","unstructured":"Ferreira, J. R., Teixeira, G. Q., Santos, S. G., Barbosa, M. A., Almeida-Porada, G., & Goncalves, R. M. (2018). Mesenchymal stromal cell secretome: Influencing therapeutic potential by cellular Pre-conditioning. Frontiers in Immunology, 9, 2837. https:\/\/doi.org\/10.3389\/fimmu.2018.02837","journal-title":"Frontiers in Immunology"},{"issue":"2","key":"11082_CR33","doi-asserted-by":"publisher","first-page":"e12404","DOI":"10.1002\/jev2.12404","volume":"13","author":"JA Welsh","year":"2024","unstructured":"Welsh, J. A., Goberdhan, D. C. I., O\u2019Driscoll, L., Buzas, E. I., Blenkiron, C., Bussolati, B., et al. (2024). Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. J Extracell Vesicles, 13(2), e12404. https:\/\/doi.org\/10.1002\/jev2.12404","journal-title":"J Extracell Vesicles"},{"key":"11082_CR34","doi-asserted-by":"publisher","unstructured":"Eleuteri, S., & Fierabracci, A. (2019). Insights into the secretome of mesenchymal stem cells and its potential applications. International Journal of Molecular Sciences, 20(18). https:\/\/doi.org\/10.3390\/ijms20184597","DOI":"10.3390\/ijms20184597"},{"issue":"1","key":"11082_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jcyt.2024.07.014","volume":"27","author":"TT Tan","year":"2025","unstructured":"Tan, T. T., Lai, R. C., Sim, W. K., Zhang, B., & Lim, S. K. (2025). Enhancing EV-cell communication through external modulation of cell by EV (EMCEV). Cytotherapy, 27(1), 1\u20136. https:\/\/doi.org\/10.1016\/j.jcyt.2024.07.014","journal-title":"Cytotherapy"},{"issue":"3","key":"11082_CR36","doi-asserted-by":"publisher","first-page":"527","DOI":"10.20517\/evcna.2024.16","volume":"5","author":"G Cerrotti","year":"2024","unstructured":"Cerrotti, G., Buratta, S., Latella, R., Calzoni, E., Cusumano, G., Bertoldi, A., et al. (2024). Hitting the target: Cell signaling pathways modulation by extracellular vesicles. Extracell Vesicles Circ Nucl Acids, 5(3), 527\u2013552. https:\/\/doi.org\/10.20517\/evcna.2024.16","journal-title":"Extracell Vesicles Circ Nucl Acids"},{"issue":"1","key":"11082_CR37","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s12967-017-1303-8","volume":"15","author":"J Vieira de Castro","year":"2017","unstructured":"Vieira de Castro, J., Gomes, E. D., Granja, S., Anjo, S. I., Baltazar, F., Manadas, B., et al. (2017). Impact of mesenchymal stem cells\u2019 secretome on glioblastoma pathophysiology. J Transl Med, 15(1), 200. https:\/\/doi.org\/10.1186\/s12967-017-1303-8","journal-title":"J Transl Med"},{"key":"11082_CR38","doi-asserted-by":"publisher","unstructured":"Harrell, C. R., Fellabaum, C., Jovicic, N., Djonov, V., Arsenijevic, N., & Volarevic, V. (2019). Molecular mechanisms responsible for therapeutic potential of mesenchymal stem Cell-Derived secretome. Cells, 8(5). https:\/\/doi.org\/10.3390\/cells8050467","DOI":"10.3390\/cells8050467"},{"key":"11082_CR39","doi-asserted-by":"publisher","unstructured":"Slama, Y., Ah-Pine, F., Khettab, M., Arcambal, A., Begue, M., Dutheil, F., et al. (2023). The dual role of mesenchymal stem cells in cancer pathophysiology: Pro-Tumorigenic effects versus therapeutic potential. International Journal of Molecular Sciences, 24(17). https:\/\/doi.org\/10.3390\/ijms241713511","DOI":"10.3390\/ijms241713511"},{"key":"11082_CR40","doi-asserted-by":"publisher","first-page":"109389","DOI":"10.1155\/2014\/109389","volume":"2014","author":"C Yang","year":"2014","unstructured":"Yang, C., Lei, D., Ouyang, W., Ren, J., Li, H., Hu, J., et al. (2014). Conditioned media from human adipose tissue-derived mesenchymal stem cells and umbilical cord-derived mesenchymal stem cells efficiently induced the apoptosis and differentiation in human glioma cell lines in vitro. Biomed Research International, 2014, 109389. https:\/\/doi.org\/10.1155\/2014\/109389","journal-title":"Biomed Research International"},{"issue":"6","key":"11082_CR41","doi-asserted-by":"publisher","first-page":"35","DOI":"10.21315\/mjms2019.26.6.4","volume":"26","author":"NS Hardiany","year":"2019","unstructured":"Hardiany, N. S., Yo, E. C., Ngadiono, E., & Wanandi, S. I. (2019). Gene expression of molecules regulating apoptotic pathways in glioblastoma multiforme treated with umbilical cord stem cell conditioned medium. Malays J Med Sci, 26(6), 35\u201345. https:\/\/doi.org\/10.21315\/mjms2019.26.6.4","journal-title":"Malays J Med Sci"},{"issue":"9","key":"11082_CR42","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1089\/scd.2012.0486","volume":"22","author":"K Akimoto","year":"2013","unstructured":"Akimoto, K., Kimura, K., Nagano, M., Takano, S., To\u2019a Salazar, G., Yamashita, T., et al. (2013). Umbilical cord blood-derived mesenchymal stem cells inhibit, but adipose tissue-derived mesenchymal stem cells promote, glioblastoma multiforme proliferation. Stem Cells and Development, 22(9), 1370\u20131386. https:\/\/doi.org\/10.1089\/scd.2012.0486","journal-title":"Stem Cells and Development"},{"key":"11082_CR43","doi-asserted-by":"publisher","first-page":"584710","DOI":"10.3389\/pore.2021.584710","volume":"27","author":"N Aslam","year":"2021","unstructured":"Aslam, N., Abusharieh, E., Abuarqoub, D., Alhattab, D., Jafar, H., Alshaer, W., et al. (2021). An in vitro comparison of Anti-Tumoral potential of wharton\u2019s jelly and bone marrow mesenchymal stem cells exhibited by cell cycle arrest in glioma cells (U87MG). Pathology Oncology Research : Por, 27, 584710. https:\/\/doi.org\/10.3389\/pore.2021.584710","journal-title":"Pathology Oncology Research : Por"},{"issue":"1","key":"11082_CR44","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.canlet.2013.02.019","volume":"335","author":"M Katakowski","year":"2013","unstructured":"Katakowski, M., Buller, B., Zheng, X., Lu, Y., Rogers, T., Osobamiro, O., et al. (2013). Exosomes from marrow stromal cells expressing miR-146b inhibit glioma growth. Cancer Letters, 335(1), 201\u2013204. https:\/\/doi.org\/10.1016\/j.canlet.2013.02.019","journal-title":"Cancer Letters"},{"issue":"6","key":"11082_CR45","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1111\/cas.15789","volume":"114","author":"Y Furusaka","year":"2023","unstructured":"Furusaka, Y., Inoue, S., Mizoguchi, I., Hasegawa, H., Katahira, Y., Watanabe, A., et al. (2023). Potent antitumor effects of the conditioned medium of bone marrow-derived mesenchymal stem cells via IGFBP-4. Cancer Science, 114(6), 2499\u20132514. https:\/\/doi.org\/10.1111\/cas.15789","journal-title":"Cancer Science"},{"issue":"1","key":"11082_CR46","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3892\/mmr.2015.3409","volume":"12","author":"C Shen","year":"2015","unstructured":"Shen, C., Lie, P., Miao, T., Yu, M., Lu, Q., Feng, T., et al. (2015). Conditioned medium from umbilical cord mesenchymal stem cells induces migration and angiogenesis. Molecular Medicine Reports, 12(1), 20\u201330. https:\/\/doi.org\/10.3892\/mmr.2015.3409","journal-title":"Molecular Medicine Reports"},{"issue":"15","key":"11082_CR47","doi-asserted-by":"publisher","first-page":"25482","DOI":"10.18632\/oncotarget.16041","volume":"8","author":"B Breznik","year":"2017","unstructured":"Breznik, B., Motaln, H., Vittori, M., Rotter, A., & Lah Turnsek, T. (2017). Mesenchymal stem cells differentially affect the invasion of distinct glioblastoma cell lines. Oncotarget, 8(15), 25482\u201325499. https:\/\/doi.org\/10.18632\/oncotarget.16041","journal-title":"Oncotarget"},{"key":"11082_CR48","doi-asserted-by":"publisher","first-page":"4952876","DOI":"10.1155\/2021\/4952876","volume":"2021","author":"S Li","year":"2021","unstructured":"Li, S., Xiang, W., Tian, J., Wang, H., Hu, S., Wang, K., et al. (2021). Bone Marrow-Derived mesenchymal stem cells differentially affect glioblastoma cell Proliferation, Migration, and invasion: A 2D-DIGE proteomic analysis. Biomed Research International, 2021, 4952876. https:\/\/doi.org\/10.1155\/2021\/4952876","journal-title":"Biomed Research International"},{"key":"11082_CR49","doi-asserted-by":"publisher","first-page":"102224","DOI":"10.1016\/j.tice.2023.102224","volume":"85","author":"S Jafari","year":"2023","unstructured":"Jafari, S., Hamidian, M., Dashtaki, M. E., Barzegar, A., & Ghasemi, S. (2023). Adipose-derived mesenchymal stem cells -conditioned medium effects on glioma U87 cell line migration, apoptosis, and gene expression. Tissue and Cell, 85, 102224. https:\/\/doi.org\/10.1016\/j.tice.2023.102224","journal-title":"Tissue and Cell"},{"issue":"11","key":"11082_CR50","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1002\/sctm.20-0161","volume":"9","author":"A Bajetto","year":"2020","unstructured":"Bajetto, A., Thellung, S., Dellacasagrande, I., Pagano, A., Barbieri, F., & Florio, T. (2020). Cross talk between mesenchymal and glioblastoma stem cells: Communication beyond controversies. Stem Cells Transl Med, 9(11), 1310\u20131330. https:\/\/doi.org\/10.1002\/sctm.20-0161","journal-title":"Stem Cells Transl Med"},{"key":"11082_CR51","doi-asserted-by":"publisher","first-page":"312","DOI":"10.3389\/fncel.2017.00312","volume":"11","author":"A Bajetto","year":"2017","unstructured":"Bajetto, A., Pattarozzi, A., Corsaro, A., Barbieri, F., Daga, A., Bosio, A., et al. (2017). Different effects of human umbilical cord mesenchymal stem cells on glioblastoma stem cells by direct cell interaction or via released soluble factors. Frontiers in Cellular Neuroscience, 11, 312. https:\/\/doi.org\/10.3389\/fncel.2017.00312","journal-title":"Frontiers in Cellular Neuroscience"},{"issue":"8","key":"11082_CR52","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.1002\/stem.2053","volume":"33","author":"A Hossain","year":"2015","unstructured":"Hossain, A., Gumin, J., Gao, F., Figueroa, J., Shinojima, N., Takezaki, T., et al. (2015). Mesenchymal stem cells isolated from human gliomas increase proliferation and maintain stemness of glioma stem cells through the IL-6\/gp130\/STAT3 pathway. Stem Cells, 33(8), 2400\u20132415. https:\/\/doi.org\/10.1002\/stem.2053","journal-title":"Stem Cells"},{"issue":"2","key":"11082_CR53","doi-asserted-by":"publisher","first-page":"346","DOI":"10.18632\/oncotarget.868","volume":"4","author":"HK Lee","year":"2013","unstructured":"Lee, H. K., Finniss, S., Cazacu, S., Bucris, E., Ziv-Av, A., Xiang, C., et al. (2013). Mesenchymal stem cells deliver synthetic MicroRNA mimics to glioma cells and glioma stem cells and inhibit their cell migration and self-renewal. Oncotarget, 4(2), 346\u2013361. https:\/\/doi.org\/10.18632\/oncotarget.868","journal-title":"Oncotarget"},{"issue":"2","key":"11082_CR54","doi-asserted-by":"publisher","first-page":"74","DOI":"10.54457\/DR.202302006","volume":"3","author":"P Prateeksha","year":"2023","unstructured":"Prateeksha, P., Howlader, M. S. I., Hansda, S., Naidu, P., Das, M., Abo-Aziza, F., et al. (2023). Secretome of dental Pulp-Derived stem cells reduces inflammation and proliferation of glioblastoma cells by deactivating Mapk-Akt pathway. Dis Res, 3(2), 74\u201386. https:\/\/doi.org\/10.54457\/DR.202302006","journal-title":"Dis Res"},{"issue":"2","key":"11082_CR55","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/cyto.a.24299","volume":"99","author":"MM Pillat","year":"2021","unstructured":"Pillat, M. M., Oliveira-Giacomelli, A., das Neves Oliveira, M., Andrejew, R., Turrini, N., Baranova, J., et al. (2021). Mesenchymal stem cell-glioblastoma interactions mediated via Kinin receptors unveiled by cytometry. Cytometry. Part A, 99(2), 152\u2013163. https:\/\/doi.org\/10.1002\/cyto.a.24299","journal-title":"Cytometry. Part A"},{"issue":"7","key":"11082_CR56","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.jcyt.2016.03.299","volume":"18","author":"GR Onzi","year":"2016","unstructured":"Onzi, G. R., Ledur, P. F., Hainzenreder, L. D., Bertoni, A. P., Silva, A. O., Lenz, G., et al. (2016). Analysis of the safety of mesenchymal stromal cells secretome for glioblastoma treatment. Cytotherapy, 18(7), 828\u2013837. https:\/\/doi.org\/10.1016\/j.jcyt.2016.03.299","journal-title":"Cytotherapy"},{"issue":"32","key":"11082_CR57","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.18632\/oncotarget.26903","volume":"10","author":"KJ Meade","year":"2019","unstructured":"Meade, K. J., Sanchez, F., Aguayo, A., Nadales, N., Hamalian, S. G., Uhlendorf, T. L., et al. (2019). Secretomes from metastatic breast cancer cells, enriched for a prognostically unfavorable LCN2 axis, induce anti-inflammatory MSC actions and a tumor-supportive premetastatic lung. Oncotarget, 10(32), 3027\u20133039. https:\/\/doi.org\/10.18632\/oncotarget.26903","journal-title":"Oncotarget"},{"key":"11082_CR58","doi-asserted-by":"publisher","unstructured":"Pietrobono, D., Giacomelli, C., Marchetti, L., Martini, C., & Trincavelli, M. L. (2020). High adenosine extracellular levels induce glioblastoma aggressive traits modulating the mesenchymal stromal cell secretome. International Journal of Molecular Sciences, 21(20). https:\/\/doi.org\/10.3390\/ijms21207706","DOI":"10.3390\/ijms21207706"},{"issue":"1","key":"11082_CR59","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1186\/s13287-018-1049-0","volume":"9","author":"LF Pavon","year":"2018","unstructured":"Pavon, L. F., Sibov, T. T., de Souza, A. V., da Cruz, E. F., Malheiros, S. M. F., Cabral, F. R., et al. (2018). Tropism of mesenchymal stem cell toward CD133(+) stem cell of glioblastoma in vitro and promote tumor proliferation in vivo. Stem Cell Research & Therapy, 9(1), 310. https:\/\/doi.org\/10.1186\/s13287-018-1049-0","journal-title":"Stem Cell Research & Therapy"},{"issue":"1","key":"11082_CR60","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1038\/s41467-024-46597-x","volume":"15","author":"C Spinelli","year":"2024","unstructured":"Spinelli, C., Adnani, L., Meehan, B., Montermini, L., Huang, S., Kim, M., et al. (2024). Mesenchymal glioma stem cells trigger vasectasia-distinct neovascularization process stimulated by extracellular vesicles carrying EGFR. Nature Communications, 15(1), 2865. https:\/\/doi.org\/10.1038\/s41467-024-46597-x","journal-title":"Nature Communications"},{"issue":"2","key":"11082_CR61","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/cdd.2011.89","volume":"19","author":"M Fareh","year":"2012","unstructured":"Fareh, M., Turchi, L., Virolle, V., Debruyne, D., Almairac, F., de-la-Forest Divonne, S., et al. (2012). The MiR 302\u2013367 cluster drastically affects self-renewal and infiltration properties of glioma-initiating cells through CXCR4 repression and consequent disruption of the SHH-GLI-NANOG network. Cell Death and Differentiation, 19(2), 232\u2013244. https:\/\/doi.org\/10.1038\/cdd.2011.89","journal-title":"Cell Death and Differentiation"},{"issue":"5","key":"11082_CR62","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1158\/1078-0432.CCR-15-2888","volume":"23","author":"AA Calinescu","year":"2017","unstructured":"Calinescu, A. A., Yadav, V. N., Carballo, E., Kadiyala, P., Tran, D., Zamler, D. B., et al. (2017). Survival and proliferation of neural Progenitor-Derived glioblastomas under hypoxic stress is controlled by a CXCL12\/CXCR4 Autocrine-Positive feedback mechanism. Clinical Cancer Research, 23(5), 1250\u20131262. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2888","journal-title":"Clinical Cancer Research"},{"key":"11082_CR63","doi-asserted-by":"publisher","first-page":"116837","DOI":"10.1016\/j.jns.2020.116837","volume":"414","author":"S Wang","year":"2020","unstructured":"Wang, S., Chen, C., Li, J., Xu, X., Chen, W., & Li, F. (2020). The CXCL12\/CXCR4 axis confers Temozolomide resistance to human glioblastoma cells via up-regulation of FOXM1. Journal of the Neurological Sciences, 414, 116837. https:\/\/doi.org\/10.1016\/j.jns.2020.116837","journal-title":"Journal of the Neurological Sciences"},{"issue":"7","key":"11082_CR64","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.it.2007.05.007","volume":"28","author":"I Petit","year":"2007","unstructured":"Petit, I., Jin, D., & Rafii, S. (2007). The SDF-1-CXCR4 signaling pathway: A molecular hub modulating neo-angiogenesis. Trends in Immunology, 28(7), 299\u2013307. https:\/\/doi.org\/10.1016\/j.it.2007.05.007","journal-title":"Trends in Immunology"},{"key":"11082_CR65","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.canlet.2018.04.042","volume":"429","author":"G Jimenez","year":"2018","unstructured":"Jimenez, G., Hackenberg, M., Catalina, P., Boulaiz, H., Grinan-Lison, C., Garcia, M. A., et al. (2018). Mesenchymal stem cell\u2019s secretome promotes selective enrichment of cancer stem-like cells with specific cytogenetic profile. Cancer Letters, 429, 78\u201388. https:\/\/doi.org\/10.1016\/j.canlet.2018.04.042","journal-title":"Cancer Letters"},{"issue":"1","key":"11082_CR66","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/s41467-022-28523-1","volume":"13","author":"VM Ravi","year":"2022","unstructured":"Ravi, V. M., Neidert, N., Will, P., Joseph, K., Maier, J. P., Kuckelhaus, J., et al. (2022). T-cell dysfunction in the glioblastoma microenvironment is mediated by myeloid cells releasing interleukin-10. Nature Communications, 13(1), 925. https:\/\/doi.org\/10.1038\/s41467-022-28523-1","journal-title":"Nature Communications"},{"key":"11082_CR67","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.3389\/fimmu.2020.01371","volume":"11","author":"Y Yang","year":"2020","unstructured":"Yang, Y., Li, C., Liu, T., Dai, X., & Bazhin, A. V. (2020). Myeloid-Derived suppressor cells in tumors: From mechanisms to antigen specificity and microenvironmental regulation. Frontiers in Immunology, 11, 1371. https:\/\/doi.org\/10.3389\/fimmu.2020.01371","journal-title":"Frontiers in Immunology"},{"issue":"11","key":"11082_CR68","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1038\/s41416-021-01515-6","volume":"125","author":"SS Widodo","year":"2021","unstructured":"Widodo, S. S., Dinevska, M., Furst, L. M., Stylli, S. S., & Mantamadiotis, T. (2021). IL-10 in glioma. British Journal of Cancer, 125(11), 1466\u20131476. https:\/\/doi.org\/10.1038\/s41416-021-01515-6","journal-title":"British Journal of Cancer"},{"issue":"3","key":"11082_CR69","doi-asserted-by":"publisher","first-page":"49","DOI":"10.37796\/2211-8039.1416","volume":"13","author":"A Arfianti","year":"2023","unstructured":"Arfianti, A., Ulfah, Hutabarat, L. S., Agnes Ivana, G., Budiarti, A. D., Sahara, N. S., et al. (2023). Hipoxia modulates the secretion of growth factors of human umbilical cord-derived mesenchymal stem cells. Biomedicine (Taipei), 13(3), 49\u201356. https:\/\/doi.org\/10.37796\/2211-8039.1416","journal-title":"Biomedicine (Taipei)"},{"issue":"7","key":"11082_CR70","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1093\/neuonc\/now258","volume":"19","author":"N Colwell","year":"2017","unstructured":"Colwell, N., Larion, M., Giles, A. J., Seldomridge, A. N., Sizdahkhani, S., Gilbert, M. R., et al. (2017). Hypoxia in the glioblastoma microenvironment: Shaping the phenotype of cancer stem-like cells. Neuro Oncol, 19(7), 887\u2013896. https:\/\/doi.org\/10.1093\/neuonc\/now258","journal-title":"Neuro Oncol"},{"issue":"10","key":"11082_CR71","doi-asserted-by":"publisher","first-page":"845","DOI":"10.5306\/wjco.v12.i10.845","volume":"12","author":"HS Marques","year":"2021","unstructured":"Marques, H. S., de Brito, B. B., da Silva, F. A. F., Santos, M. L. C., de Souza, J. C. B., Correia, T. M. L., et al. (2021). Relationship between Th17 immune response and cancer. World Journal of Clinical Oncology, 12(10), 845\u2013867. https:\/\/doi.org\/10.5306\/wjco.v12.i10.845","journal-title":"World Journal of Clinical Oncology"},{"key":"11082_CR72","doi-asserted-by":"publisher","first-page":"1479505","DOI":"10.3389\/fimmu.2024.1479505","volume":"15","author":"X Zhang","year":"2024","unstructured":"Zhang, X., Li, B., Lan, T., Chiari, C., Ye, X., Wang, K., et al. (2024). The role of interleukin-17 in inflammation-related cancers. Frontiers in Immunology, 15, 1479505. https:\/\/doi.org\/10.3389\/fimmu.2024.1479505","journal-title":"Frontiers in Immunology"},{"key":"11082_CR73","doi-asserted-by":"publisher","first-page":"1384249","DOI":"10.3389\/fimmu.2024.1384249","volume":"15","author":"L Feldman","year":"2024","unstructured":"Feldman, L. (2024). Hypoxia within the glioblastoma tumor microenvironment: A master saboteur of novel treatments. Frontiers in Immunology, 15, 1384249. https:\/\/doi.org\/10.3389\/fimmu.2024.1384249","journal-title":"Frontiers in Immunology"},{"issue":"1","key":"11082_CR74","doi-asserted-by":"publisher","first-page":"7246","DOI":"10.1038\/s41598-024-56102-5","volume":"14","author":"VJ Marallano","year":"2024","unstructured":"Marallano, V. J., Ughetta, M. E., Tejero, R., Nanda, S., Ramalingam, R., Stalbow, L., et al. (2024). Hypoxia drives shared and distinct transcriptomic changes in two invasive glioma stem cell lines. Scientific Reports, 14(1), 7246. https:\/\/doi.org\/10.1038\/s41598-024-56102-5","journal-title":"Scientific Reports"},{"issue":"2","key":"11082_CR75","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jcyt.2015.11.008","volume":"18","author":"J Galipeau","year":"2016","unstructured":"Galipeau, J., Krampera, M., Barrett, J., Dazzi, F., Deans, R. J., DeBruijn, J., et al. (2016). International society for cellular therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. Cytotherapy, 18(2), 151\u2013159. https:\/\/doi.org\/10.1016\/j.jcyt.2015.11.008","journal-title":"Cytotherapy"},{"issue":"11","key":"11082_CR76","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1093\/stmcls\/sxad060","volume":"41","author":"AJ Turlo","year":"2023","unstructured":"Turlo, A. J., Hammond, D. E., Ramsbottom, K. A., Soul, J., Gillen, A., McDonald, K., et al. (2023). Mesenchymal stromal cell secretome is affected by tissue source and donor age. Stem Cells, 41(11), 1047\u20131059. https:\/\/doi.org\/10.1093\/stmcls\/sxad060","journal-title":"Stem Cells"},{"key":"11082_CR77","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/978-3-030-11096-3_8","volume":"1123","author":"EA Prieto Gonzalez","year":"2019","unstructured":"Prieto Gonzalez, E. A. (2019). Heterogeneity in adipose stem cells. Advances in Experimental Medicine and Biology, 1123, 119\u2013150. https:\/\/doi.org\/10.1007\/978-3-030-11096-3_8","journal-title":"Advances in Experimental Medicine and Biology"},{"issue":"9","key":"11082_CR78","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1177\/0963689717721203","volume":"26","author":"D Dufrane","year":"2017","unstructured":"Dufrane, D. (2017). Impact of age on human adipose stem cells for bone tissue engineering. Cell Transplantation, 26(9), 1496\u20131504. https:\/\/doi.org\/10.1177\/0963689717721203","journal-title":"Cell Transplantation"},{"issue":"1","key":"11082_CR79","doi-asserted-by":"publisher","first-page":"4373","DOI":"10.1038\/s41467-023-39958-5","volume":"14","author":"Y Gao","year":"2023","unstructured":"Gao, Y., Chi, Y., Chen, Y., Wang, W., Li, H., Zheng, W., et al. (2023). Multi-omics analysis of human mesenchymal stem cells shows cell aging that alters Immunomodulatory activity through the downregulation of PD-L1. Nature Communications, 14(1), 4373. https:\/\/doi.org\/10.1038\/s41467-023-39958-5","journal-title":"Nature Communications"},{"issue":"6","key":"11082_CR80","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s13770-018-0147-5","volume":"15","author":"CH Mun","year":"2018","unstructured":"Mun, C. H., Kang, M. I., Shin, Y. D., Kim, Y., & Park, Y. B. (2018). The expression of Immunomodulation-Related cytokines and genes of Adipose- and bone Marrow-Derived human mesenchymal stromal cells from early to late passages. Tissue Eng Regen Med, 15(6), 771\u2013779. https:\/\/doi.org\/10.1007\/s13770-018-0147-5","journal-title":"Tissue Eng Regen Med"},{"issue":"1","key":"11082_CR81","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41536-024-00382-y","volume":"10","author":"M Hodgson-Garms","year":"2025","unstructured":"Hodgson-Garms, M., Moore, M. J., Martino, M. M., Kelly, K., & Frith, J. E. (2025). Proteomic profiling of iPSC and tissue-derived MSC secretomes reveal a global signature of inflammatory licensing. NPJ Regen Med, 10(1), 7. https:\/\/doi.org\/10.1038\/s41536-024-00382-y","journal-title":"NPJ Regen Med"},{"issue":"2","key":"11082_CR82","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/eji.201948336","volume":"51","author":"A Hackel","year":"2021","unstructured":"Hackel, A., Aksamit, A., Bruderek, K., Lang, S., & Brandau, S. (2021). TNF-alpha and IL-1beta sensitize human MSC for IFN-gamma signaling and enhance neutrophil recruitment. European Journal of Immunology, 51(2), 319\u2013330. https:\/\/doi.org\/10.1002\/eji.201948336","journal-title":"European Journal of Immunology"},{"issue":"8","key":"11082_CR83","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1634\/stemcells.2007-1104","volume":"26","author":"I Rosova","year":"2008","unstructured":"Rosova, I., Dao, M., Capoccia, B., Link, D., & Nolta, J. A. (2008). Hypoxic preconditioning results in increased motility and improved therapeutic potential of human mesenchymal stem cells. Stem Cells, 26(8), 2173\u20132182. https:\/\/doi.org\/10.1634\/stemcells.2007-1104","journal-title":"Stem Cells"},{"issue":"1","key":"11082_CR84","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s13287-025-04315-4","volume":"16","author":"M Rossello-Gelabert","year":"2025","unstructured":"Rossello-Gelabert, M., Igartua, M., Santos-Vizcaino, E., & Hernandez, R. M. (2025). Fine-tuning licensing strategies to boost MSC-based Immunomodulatory secretome. Stem Cell Research & Therapy, 16(1), 183. https:\/\/doi.org\/10.1186\/s13287-025-04315-4","journal-title":"Stem Cell Research & Therapy"},{"issue":"1","key":"11082_CR85","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1186\/s13287-023-03563-6","volume":"14","author":"J Faria","year":"2023","unstructured":"Faria, J., Calcat, I. C. S., Skovronova, R., Broeksma, B. C., Berends, A. J., Zaal, E. A., et al. (2023). Mesenchymal stromal cells secretome restores bioenergetic and redox homeostasis in human proximal tubule cells after ischemic injury. Stem Cell Research & Therapy, 14(1), 353. https:\/\/doi.org\/10.1186\/s13287-023-03563-6","journal-title":"Stem Cell Research & Therapy"},{"issue":"5","key":"11082_CR86","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.7150\/thno.77597","volume":"13","author":"MEF Palama","year":"2023","unstructured":"Palama, M. E. F., Coco, S., Shaw, G. M., Reverberi, D., Ghelardoni, M., Ostano, P., et al. (2023). Xeno-free cultured mesenchymal stromal cells release extracellular vesicles with a therapeutic MiRNA cargo ameliorating cartilage inflammation in vitro. Theranostics, 13(5), 1470\u20131489. https:\/\/doi.org\/10.7150\/thno.77597","journal-title":"Theranostics"},{"issue":"1","key":"11082_CR87","doi-asserted-by":"publisher","first-page":"10243","DOI":"10.1038\/s41598-024-60787-z","volume":"14","author":"O Rogulska","year":"2024","unstructured":"Rogulska, O., Vackova, I., Prazak, S., Turnovcova, K., Kubinova, S., Bacakova, L., et al. (2024). Storage conditions affect the composition of the lyophilized secretome of multipotent mesenchymal stromal cells. Scientific Reports, 14(1), 10243. https:\/\/doi.org\/10.1038\/s41598-024-60787-z","journal-title":"Scientific Reports"},{"issue":"2","key":"11082_CR88","doi-asserted-by":"publisher","first-page":"e12162","DOI":"10.1002\/jev2.12162","volume":"11","author":"S Gelibter","year":"2022","unstructured":"Gelibter, S., Marostica, G., Mandelli, A., Siciliani, S., Podini, P., Finardi, A., et al. (2022). The impact of storage on extracellular vesicles: A systematic study. J Extracell Vesicles, 11(2), e12162. https:\/\/doi.org\/10.1002\/jev2.12162","journal-title":"J Extracell Vesicles"},{"key":"11082_CR89","doi-asserted-by":"publisher","unstructured":"Thery, C., Amigorena, S., Raposo, G., & Clayton, A. (2006). Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol, Chap3\u2013Unit322. https:\/\/doi.org\/10.1002\/0471143030.cb0322s30","DOI":"10.1002\/0471143030.cb0322s30"},{"key":"11082_CR90","doi-asserted-by":"publisher","first-page":"29509","DOI":"10.3402\/jev.v4.29509","volume":"4","author":"R Linares","year":"2015","unstructured":"Linares, R., Tan, S., Gounou, C., Arraud, N., & Brisson, A. R. (2015). High-speed centrifugation induces aggregation of extracellular vesicles. J Extracell Vesicles, 4, 29509. https:\/\/doi.org\/10.3402\/jev.v4.29509","journal-title":"J Extracell Vesicles"},{"key":"11082_CR91","doi-asserted-by":"publisher","unstructured":"Yuana, Y., Levels, J., Grootemaat, A., Sturk, A., & Nieuwland, R. (2014). Co-isolation of extracellular vesicles and high-density lipoproteins using density gradient ultracentrifugation. J Extracell Vesicles, 3. https:\/\/doi.org\/10.3402\/jev.v3.23262","DOI":"10.3402\/jev.v3.23262"},{"issue":"6","key":"11082_CR92","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.1021\/acs.jproteome.5c00149","volume":"24","author":"PS Suresh","year":"2025","unstructured":"Suresh, P. S., & Zhang, Q. (2025). Comprehensive comparison of methods for isolation of extracellular vesicles from human plasma. Journal of Proteome Research, 24(6), 2956\u20132967. https:\/\/doi.org\/10.1021\/acs.jproteome.5c00149","journal-title":"Journal of Proteome Research"},{"issue":"5","key":"11082_CR93","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.jcyt.2021.01.001","volume":"23","author":"M Gimona","year":"2021","unstructured":"Gimona, M., Brizzi, M. F., Choo, A. B. H., Dominici, M., Davidson, S. M., Grillari, J., et al. (2021). Critical considerations for the development of potency tests for therapeutic applications of mesenchymal stromal cell-derived small extracellular vesicles. Cytotherapy, 23(5), 373\u2013380. https:\/\/doi.org\/10.1016\/j.jcyt.2021.01.001","journal-title":"Cytotherapy"},{"issue":"7092","key":"11082_CR94","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nature04870","volume":"441","author":"M Karin","year":"2006","unstructured":"Karin, M. (2006). Nuclear factor-kappaB in cancer development and progression. Nature, 441(7092), 431\u2013436. https:\/\/doi.org\/10.1038\/nature04870","journal-title":"Nature"},{"issue":"16","key":"11082_CR95","doi-asserted-by":"publisher","first-page":"5595","DOI":"10.1158\/1078-0432.CCR-03-0392","volume":"10","author":"PA Robe","year":"2004","unstructured":"Robe, P. A., Bentires-Alj, M., Bonif, M., Rogister, B., Deprez, M., Haddada, H., et al. (2004). In vitro and in vivo activity of the nuclear factor-kappaB inhibitor sulfasalazine in human glioblastomas. Clinical Cancer Research, 10(16), 5595\u20135603. https:\/\/doi.org\/10.1158\/1078-0432.CCR-03-0392","journal-title":"Clinical Cancer Research"},{"issue":"32","key":"11082_CR96","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1038\/onc.2011.74","volume":"30","author":"L Nogueira","year":"2011","unstructured":"Nogueira, L., Ruiz-Ontanon, P., Vazquez-Barquero, A., Lafarga, M., Berciano, M. T., Aldaz, B., et al. (2011). Blockade of the NFkappaB pathway drives differentiating glioblastoma-initiating cells into senescence both in vitro and in vivo. Oncogene, 30(32), 3537\u20133548. https:\/\/doi.org\/10.1038\/onc.2011.74","journal-title":"Oncogene"},{"issue":"3","key":"11082_CR97","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ccr.2013.08.001","volume":"24","author":"KPL Bhat","year":"2013","unstructured":"Bhat, K. P. L., Balasubramaniyan, V., Vaillant, B., Ezhilarasan, R., Hummelink, K., Hollingsworth, F., et al. (2013). Mesenchymal differentiation mediated by NF-kappaB promotes radiation resistance in glioblastoma. Cancer Cell, 24(3), 331\u2013346. https:\/\/doi.org\/10.1016\/j.ccr.2013.08.001","journal-title":"Cancer Cell"},{"issue":"2","key":"11082_CR98","doi-asserted-by":"publisher","first-page":"e12929","DOI":"10.1111\/cpr.12929","volume":"54","author":"J Tu","year":"2021","unstructured":"Tu, J., Fang, Y., Han, D., Tan, X., Jiang, H., Gong, X., et al. (2021). Activation of nuclear factor-kappaB in the angiogenesis of glioma: Insights into the associated molecular mechanisms and targeted therapies. Cell Proliferation, 54(2), e12929. https:\/\/doi.org\/10.1111\/cpr.12929","journal-title":"Cell Proliferation"},{"issue":"5","key":"11082_CR99","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nri.2017.142","volume":"18","author":"K Taniguchi","year":"2018","unstructured":"Taniguchi, K., & Karin, M. (2018). NF-kappaB, inflammation, immunity and cancer: Coming of age. Nature Reviews Immunology, 18(5), 309\u2013324. https:\/\/doi.org\/10.1038\/nri.2017.142","journal-title":"Nature Reviews Immunology"},{"key":"11082_CR100","doi-asserted-by":"publisher","first-page":"6209865","DOI":"10.1155\/2017\/6209865","volume":"2017","author":"MT Zeuner","year":"2017","unstructured":"Zeuner, M. T., Vallance, T., Vaiyapuri, S., Cottrell, G. S., & Widera, D. (2017). Development and characterisation of a novel NF-kappaB reporter cell line for investigation of neuroinflammation. Mediators Inflamm, 2017, 6209865. https:\/\/doi.org\/10.1155\/2017\/6209865","journal-title":"Mediators Inflamm"},{"issue":"8","key":"11082_CR101","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jcyt.2023.03.009","volume":"25","author":"M Bremer","year":"2023","unstructured":"Bremer, M., Nardi Bauer, F., Tertel, T., Dittrich, R., Horn, P. A., Borger, V., et al. (2023). Qualification of a multidonor mixed lymphocyte reaction assay for the functional characterization of Immunomodulatory extracellular vesicles. Cytotherapy, 25(8), 847\u2013857. https:\/\/doi.org\/10.1016\/j.jcyt.2023.03.009","journal-title":"Cytotherapy"},{"issue":"9","key":"11082_CR102","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1016\/j.celrep.2018.02.013","volume":"22","author":"R Chinnadurai","year":"2018","unstructured":"Chinnadurai, R., Rajan, D., Qayed, M., Arafat, D., Garcia, M., Liu, Y., et al. (2018). Potency analysis of mesenchymal stromal cells using a combinatorial assay matrix approach. Cell Rep, 22(9), 2504\u20132517. https:\/\/doi.org\/10.1016\/j.celrep.2018.02.013","journal-title":"Cell Rep"}],"container-title":["Stem Cell Reviews and Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12015-026-11082-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12015-026-11082-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12015-026-11082-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T06:14:14Z","timestamp":1776752054000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12015-026-11082-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,14]]},"references-count":102,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["11082"],"URL":"https:\/\/doi.org\/10.1007\/s12015-026-11082-z","relation":{},"ISSN":["2629-3269","2629-3277"],"issn-type":[{"value":"2629-3269","type":"print"},{"value":"2629-3277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,14]]},"assertion":[{"value":"12 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical Trial Number"}}]}}